Importantly, C5aR1-deficiency and pharmacological blockade of C5aR1 by selective C5aR1 antagonists have been shown to impair tumor growth, pointing to the C5a/C5aR1 signaling axis as an effector mechanism of C-mediated tumor-promoting functions (14). This evidence concerns the gene C5AR1 and neoplasm.